Nuocheng Jianhua's performance forecast shows that Obutinib's revenue will increase by forty-nine% i

On January sixteenth, Novartis (Shanghai Stock Exchange code: six hundred and eighty-eight thousand four hundred and twenty-eight; Hong Kong Stock Exchange code: nine thousand nine hundred and sixty-nine) released its annual performance forecast for two thousand twenty-four, ending on December thirty-onest.; According to preliminary calculations by the finance department, Nuocheng Jianhua expects its core product Obutinib to achieve a revenue of approximately one.one billion yuan in two thousand twenty-four, an increase of approximately forty-nine% compared to the same period last year. The total operating revenue of the company is about one.one billion yuan, an increase of about thirty-seven% compared to the same period last year. This is mainly attributed to the fact that Obutinib is the first and only BTK inhibitor approved for marketing in China for marginal zone lymphoma (MZL indication), and this new indication has achieved rapid mass production this year after being included in medical insurance in two thousand twenty-three. At the same time, the company has built a more experienced blood tumor commercialization team, further improving operational efficiency, continuously reducing sales expense rates, and continuously enhancing sustainable development capabilities.; At the same time, the company expects its net loss attributable to shareholders to narrow by about thirty% year-on-year in two thousand twenty-four, to four hundred and forty-three million yuan.